Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14160138 | 0.91 | AGTR2 (0.46) | AGTR2GPR119NR1H3NR1H2TACR1 | |
| SCHEMBL14085916 | 0.90 | NR1H3 (0.51) | AGTR2GPR119NR1H3NR1H2TACR1 | |
| SCHEMBL6337504 | 0.88 | AGTR2 (0.50) | AGTR2GPR119NR1H3NR1H2MEN1 | |
| SCHEMBL6337507 | 0.88 | AGTR2 (0.50) | AGTR2GPR119NR1H3NR1H2MEN1 | |
| SCHEMBL12845090 | 0.87 | AGTR2 (0.46) | AGTR2GPR119NR1H3NR1H2BCHE | |
| SCHEMBL8120986 | 0.86 | GPR119 (0.45) | AGTR2GPR119NR1H3NR1H2BCHE | |
| SCHEMBL13340712 | 0.86 | GPR119 (0.45) | AGTR2GPR119NR1H3NR1H2BCHE | |
| SCHEMBL3493253 | 0.85 | AGTR2 (0.50) | AGTR2MEN1KMT2ATACR1BCHE | |
| SCHEMBL4367565 | 0.84 | JAK2 (0.40) | AGTR2GPR119NR1H3NR1H2BCHE | |
| SCHEMBL4372410 | 0.84 | JAK2 (0.40) | AGTR2GPR119NR1H3NR1H2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | AGTR2 3/4885GPR119 689/4885NR1H3 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.